Firm Gets Patent on Protein Group
- Share via
International Genetic Engineering Inc. said it has been issued a U.S. patent on a class of proteins named regressens--antigens associated with tumor regression.
The company said the proteins may complement other types of biological therapy, and may be used in addition to conventional approaches to cancer treatment.
It noted that considerable development work remains to determine the safety and clinical efficacy of the patented immunogens.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
